MedTrace Logo

An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine

NCT02873221 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1254

Last updated 2019-08-28

Study results available
· View outcomes & findings →

Summary

This study will evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year.

Conditions

  • Migraine, With or Without Aura

Interventions

DRUG

Ubrogepant

Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.

DRUG

Placebo-matching Ubrogepant

Ubrogepant placebo-matching tablet orally for the treatment of a qualifying migraine attack.

DRUG

Usual Care

Treatment for a migraine as prescribed by the physician as standard of care in clinical practice.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Adele Thorpe · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
76 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-13
Primary Completion
2018-08-02
Completion
2018-08-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02873221 on ClinicalTrials.gov